metabolic syndrome, Hypertriglycdimia, Diabetes mellitus
Conditions
Interventions
None listed
Sponsors
Dokkyo Medical University Nikko Medical Center Department of cardiology medicine and nephrology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who are visiting or planning to visit Dokkyo Medical University Nikko Medical Center 2) Patients who are at least 20 years old at the time of obtaining consent 3) Patients who have been diagnosed with type 2 diabetes on administration of pemafibrate and have 6% to 10% HbA1c and have not changed their diabetes treatment in the past 4 weeks or have metabolic syndrome 4) Fasting TG 150 mg / dL equivalent or higher within 2 weeks before pemafibrate administration 5) Whole blood transit time (correction value) in MCFAN within 2 weeks before pemafibrate administration 45 seconds or slower MCFAN of whole blood transit time (correction) within 2 weeks before administration of pemafibrate, plus all blood transit time (correction) within 6 weeks before administration including 2-6 weeks before administration of pemafibrate Transit time of whole blood (correction value) 6) Pemafibrate newly prescribed or scheduled to be prescribed 7) Patients who have given their written consent to participate in the study Metabolic syndrome is defined when the waist circumference (abdominal waist circumference) is 85 cm for men and 90 cm or more for women, and two or more of blood pressure, blood sugar, and lipids are out of the standard values. (Table below, Journal of the Japanese Society of Internal Medicine; 2005; 94: 188-203.) Required items (visceral fat accumulation) Waist circumference male 85 cm or more Female 90 cm or more Visceral fat area Equivalent to 100 cm2 for both men and women Selection item Out of 3 items 2 or more items 1.Hypertriglyceridemia is 150 mg / dL or more and or Low HDL cholesterol 40 mg / dL or more 2. systolic (maximum) blood pressure 130 mmHg or more And or diastolic (minimum) blood pressure 85 mmHg or more 3.Fasting hyperglycemia 110 mg / dL
Exclusion criteria
Exclusion criteria: Patients judged by the Principal Investigator or Investigator (hereinafter referred to as the Principal Investigator, etc.) to be inappropriate for participation in the research
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes from baseline in whole blood transit time in micro channel array flow analyzer(MCFAN) at 16 weeks) | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in whole blood transit time in MCFAN at 8 weeks Leukocyte activation index (adhesive leukocyte count, difference in whole blood transit time between heparin blood collection and heparin + EDTA2Na blood collection) | — |
Countries
Japan
Contacts
Public ContactTakanori Yasu
Dokkyo Medical University Nikko Medical Center Department of cardiology medicine and nephrology
Outcome results
None listed